Medicago is pursuing an aggressive discovery and development program that encompasses pandemic and trivalent vaccines, antivirals, antibodies and biologics – including biosimilars and biobetters.
Pandemic flu vaccines
Medicago successfully expressed a virus-like particle (VLP) antigen (H1 VLP) from the influenza A (H1N1) strain, known as the swine flu, which caused a major influenza outbreak in North America and other countries in 2009.
- The antigen was expressed within 14 days of receiving the DNA sequence, with the company's VLP vaccine and ProficiaTM manufacturing technologies.
- Medicago completed a phase I H1N1 influenza vaccine clinical trial in 2011. All vaccine doses were found to be safe and well tolerated, and also induced a solid immune response that met the CHMP criteria, even with a single dose of 5 µg.
- Medicago also recently reported positive results from a Phase II clinical trial with its avian flu H5 pandemic vaccine candidate. The vaccine was found to be safe, well tolerated and highly effective.
- Based on these results and subject to regulatory approval, Medicago intends to proceed with a U.S. Phase IIa trial for its seasonal trivalent vaccine with the recommended H1N1, H3N2 and B influenza strains.
Medicago’s production platform has demonstrated its important potential for responding to international emergencies and pandemics when it produced candidate vaccines for H1N1 in 2009 and H7N9 in 2013. - Andy Sheldon, Medicago CEO